Results 1 - 10 of 26 : 1 2 3 Next
Regeneron's Results Clearing Up
The drugmaker presents new data on a compelling candidate.
This bullish call comes from more than just one analyst.
Stiefel Labs snaps up the niche pharmaceutical.
Acquiring a niche acne drug from QLT provides clarity for both companies.
Get 'em fresh from the oven!
Get 'em fresh from the oven!
Actions speak louder than words.
QLT takes one step toward a winning combination for those who suffer from macular degeneration.
QLT's Blemished Aczone Clears Up
A more lenient label from the FDA is good news for the drugmaker.
Regeneron's Orphan Charms the FDA
The drug to treat a rare disease gets the OK.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK